2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data, expansion into autoimmune disease, and combination […]

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge […]